KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $1.3 billion.

  • Alnylam Pharmaceuticals' Short-term Investments fell 2725.05% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 2725.05%. This contributed to the annual value of $1.3 billion for FY2025, which is 2725.05% down from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Short-term Investments is $1.3 billion, which was down 2725.05% from $1.2 billion recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Short-term Investments high stood at $1.7 billion for Q2 2025, and its period low was $1.1 billion during Q2 2021.
  • Moreover, its 5-year median value for Short-term Investments was $1.4 billion (2022), whereas its average is $1.5 billion.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 5221.3% in 2021, then tumbled by 2725.05% in 2025.
  • Alnylam Pharmaceuticals' Short-term Investments (Quarter) stood at $1.5 billion in 2021, then fell by 16.19% to $1.3 billion in 2022, then grew by 24.47% to $1.6 billion in 2023, then grew by 6.46% to $1.7 billion in 2024, then decreased by 27.25% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.7 billion during Q2 2025.